The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going? [0.03%]
嵌合抗原受体(CAR)T细胞疗法在儿科患者中的应用：我们从哪里来？我们现在在哪里？我们将去哪里？
Tristan Knight E,Olalekan Oluwole,Carrie Kitko
Tristan Knight E
CD19-directed Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL). Somewhat uniquely among oncologic clinical trials, early clinical development occurr...
Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review [0.03%]
中东和非洲多发性骨髓瘤的流行病学、治疗趋势及结局：系统综述
Mervat Mattar,Ali Bazarbachi,Omar Abduljalil et al.
Mervat Mattar et al.
Background: Globally, multiple myeloma (MM) ranks 24th among the most common cancers. The Middle East and Africa are affected by an increasing trend in MM incidence, owing to several underlying factors. This systematic re...
Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation [0.03%]
造血干细胞移植时 Conditioning 方案相关急性毒副反应的防治
Jana Sawyer,Taylor Elliott,Lindsay Orton et al.
Jana Sawyer et al.
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for several hematological malignancies. Its use has continued to grow, with an estimated 23,500 transplants performed annually in the United States alone. The a...
Outcomes of Autologous stem cell transplantation in patients with primary refractory Diffuse Large B-cell lymphoma who demonstrate chemosensitivity to salvage chemotherapy [0.03%]
自体干细胞移植治疗对原发耐药及解救化疗敏感的大B细胞淋巴瘤患者的疗效分析
M Shahzad Rauf,Irfan Maghfoor,Muhammad Aseafan et al.
M Shahzad Rauf et al.
Rituximab with anthracycline-based combination frontline chemoimmunotherapy can cure 50-60% of patients with diffuse large B-cell lymphoma (DLBCL). However, studies on the outcomes of patients with DLBCL who experience partial response (PR)...
Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy [0.03%]
嵌合抗原受体T细胞(CAR-T)治疗相关的感染并发症管理
Nausheen Ahmed,Olalekan Oluwole,Zahra Mahmoudjafari et al.
Nausheen Ahmed et al.
Chimeric antigen receptor T-cell (CAR T-cell) therapy has changed the paradigm of management of non-Hodgkin's lymphoma (NHL) and Multiple Myeloma. Infection complications have emerged as a concern that can arise in the setting of therapy an...
Giebel Sebastian
Giebel Sebastian
Treatment algorithms differ for adult patients with Philadelphia-negative (Ph-) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). For Ph- ALL intensive induction-consolidation chemotherapy using "pediatric-inspired" protoc...
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations [0.03%]
门诊CAR-T细胞治疗的标准治疗现状及考虑因素
Katie Gatwood,Zahra Mahmoudjafari,Brittney Baer et al.
Katie Gatwood et al.
Chimeric antigen receptor T-cell therapy (CAR-T) has altered the treatment landscape of several hematologic malignancies. Until recently, most CAR-T infusions have been administered in the inpatient setting, due to their toxicity profile. H...
Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis [0.03%]
接受血液透析的多发性骨髓瘤患者使用Elranatamab治疗
Zoé Van de Wyngaert,Irene Romera-Martinez,Céline Chedeville et al.
Zoé Van de Wyngaert et al.
We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific a...
Andrew M Brunner,Uwe Platzbecker,Amy E DeZern et al.
Andrew M Brunner et al.
Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbiditi...